Corvus Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Corvus Pharmaceuticals, Inc. (CRVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.10 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2024-03-19
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $2.10M, a 25.00% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $2.80M, a 37.78% decline from fiscal 2021.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $4.50M, a 25.00% decline from fiscal 2020.
- Corvus Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $6.00M, a 23.08% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 11 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|
| 2023-12-31 | $2.10M 10-K · filed 2024-03-19 | ||
| 2022-12-31 | $2.80M 10-K · filed 2024-03-19 | ||
| 2021-12-31 | $4.50M 10-K · filed 2024-03-19 | ||
| 2020-12-31 | $6.00M 10-K · filed 2023-03-28 | ||
| 2019-12-31 | $7.80M 10-K · filed 2022-03-10 | ||
| 2018-12-31 | $7.10M 10-K · filed 2021-03-25 | ||
| 2017-12-31 | $5.80M 10-K · filed 2020-03-09 | ||
| 2016-12-31 | $3.20M 10-K · filed 2019-03-07 | $3.19M 10-K · filed 2017-03-10 | |
| 2015-12-31 | $100.00K 10-K · filed 2018-03-01 | $75.00K 10-K · filed 2017-03-10 | |
| 2014-12-31 | $100.00 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |